Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $5.39M rose 24.8% year over year, ahead of the +22.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 23.1% from the prior quarter. Over 3 fiscal years it compounded at -7.6% a year.
Context
- Selling, general & admin amounted to 418.6% of revenue in FY2025, down 314.2 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $13.82M (-18.6%) for the fiscal year ending Dec 2026, a slowdown from the +23.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.39M+23.1% QoQ
- Last fiscal yearDec 2025
- $16.98M+23.1% YoY
- LTMMar 2026
- $17.81M+22.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 16.98M USD
- Year-over-year change
- +23.1%
- 4-year CAGR
- -4.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.98M | +23.1% |
| FY2024 | 2024-12-31 | 13.79M | +3.8% |
| FY2023 | 2023-12-31 | 13.29M | -38.3% |
| FY2022 | 2022-12-31 | 21.53M | +5.6% |
| FY2021 | 2021-12-31 | 20.39M | — |
Selling, General & Admin vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 selling, general & admin of $17.81M is the 9th highest of the 10 companies compared; the peer median is $31.65M.
- Its year-over-year change of +22.1% is the highest of 10, against a peer median of -12.7%.
- Selling, general & admin amounts to 914.0% of revenue for IMDX, versus a peer median of 113.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.78M | +14.7% | +12.5% | 133.9% | |
| LTM Mar 2026 | $43.75M | -19.9% | -3.4% | 56.0% | |
| LTM Mar 2026 | $34.83M | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $34.4M | -16.4% | -5.4% | 98.7% | |
| LTM Mar 2026 | $31.65M | -26.4% | -17.7% | 91.6% | |
| LTM Mar 2026 | $26.47M | -12.7% | +5.5% | 91.6% | |
| LTM Mar 2026 | $22.56M | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $21.38M | -22.5% | -9.9% | 127.9% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $17.81M | +22.1% | -7.6% | 914.0% |
| LTM Mar 2026 | $12.62M | -4.8% | +18.6% | 426.6% | |
| Peer median (excluding IMDX) | $31.65M | -12.7% | -3.4% | 113.3% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.2M | 958K | 1.5M | 1.88M | 4.06M |
| Cost of Revenue | 778K | 976K | 1.09M | 1.14M | 3.87M |
| Gross Profit | 1.42M | (18K) | 413K | 740K | 190K |
| Gross Margin | 64.6% | -1.9% | 27.5% | 39.3% | 4.7% |
| Research & Development | 5.04M | 7.3M | 9.29M | 9.84M | 15.9M |
| Selling, General & Admin | 20.39M | 21.53M | 13.29M | 13.79M | 16.98M |
| Operating Expenses | 55.15M | 17.98M | 25.55M | 61.78M | 30.77M |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| EBITDA | (48.46M) | (13.31M) | (23.12M) | (59.02M) | (47.92M) |
| EBITDA Margin | -2204.6% | -1389.2% | -1538.5% | -3137.4% | -1181.7% |
| Operating Income | (53.73M) | (18M) | (25.14M) | (61.04M) | (30.58M) |
| Operating Margin | -2444.3% | -1878.6% | -1672.4% | -3245.1% | -754.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 209K | 83K | 52K | 84K | 109K |
| Other Income / Expenses | 854K | (615K) | 281K | 378K | (19.64M) |
| Income Before Tax | (52.87M) | (18.61M) | (24.86M) | (60.66M) | (50.22M) |
| Pre-Tax Margin | -2405.4% | -1942.8% | -1653.7% | -3225.0% | -1238.5% |
| Income Tax Expense | (9.26M) | 0 | 0 | 0 | 0 |
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Net Margin | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
| EPS (Basic) | (14.40) | (20.00) | (3.75) | (4.66) | (1.65) |
| EPS (Diluted) | (14.40) | (20.00) | (3.75) | (4.66) | (1.65) |
| Weighted Avg Shares | 4.45M | 5.54M | 7.65M | 13.07M | 30.48M |
| Weighted Avg Shares (Diluted) | 4.45M | 5.54M | 7.65M | 13.07M | 30.48M |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.